A5086078595- Airway Management and Intubation Techniques
- Cancer Research and Treatments
- Virus-based gene therapy research
- Anesthesia and Sedative Agents
- Respiratory Support and Mechanisms
- Tracheal and airway disorders
- Adrenal Hormones and Disorders
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- RNA modifications and cancer
- Immunotherapy and Immune Responses
The University of Texas Southwestern Medical Center
2018-2019
Parkland Memorial Hospital
2019
Texas Oncology
2006
Mary Crowley Cancer Research Center
2006
L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene injected intramuscularly as expressive plasmid (pVAX/L523S) and delivered following incorporation into E1B-deleted adenovirus (Ad/L523S). We performed a phase I clinical trial in 13 stage IB, IIA, IIB non-small-cell patients. pVAX/L523S (8 mg on days 0 14 all cohorts) Ad/L523S (1, 20, 400 × 109 vp 28 56, cohorts 1, 2, 3, respectively) were administered to 3 patients each of three cohorts. No...